STOCK TITAN

Hookipa Pharma - HOOK STOCK NEWS

Welcome to our dedicated page for Hookipa Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma stock.

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company pioneering arenavirus-based immunotherapies for cancer and infectious diseases. This page aggregates official announcements, including clinical trial updates, regulatory milestones, and strategic partnerships, providing investors and researchers a centralized resource for tracking the company’s progress.

Users will find timely updates on HOOKIPA’s Vaxwave® and Therat® platforms, which leverage viral vector technology to stimulate durable immune responses. Key content includes trial results for HPV16+ head and neck cancer therapies, hepatitis B/HIV collaboration updates, and financial disclosures. The platform’s stakeholders to monitor developments in immunotherapy approaches designed to overcome traditional treatment limitations.

Bookmark this page for direct access to press releases, SEC filings, and event transcripts. Check regularly for updates on HOOKIPA’s pipeline advancements and industry collaborations that shape its position in the immuno-oncology landscape.

Rhea-AI Summary

HOOKIPA Pharma announced updated Phase 2 clinical data for HB-200 combined with pembrolizumab in treating recurrent/metastatic HPV16+ head and neck cancer at the ASCO 2024 Annual Meeting. Out of 35 evaluable patients, results showed a 37% confirmed objective response rate (ORR), 11% complete response (CR) rate, and 69% disease control rate (DCR). Notably, in a subset of 17 patients with a PD-L1 CPS of 20 or higher, the ORR was 53%, CR rate 18%, and DCR 82%. Preliminary progression-free survival (PFS) for this subset was 16.3 months, with a 9-month overall survival (OS) rate of 88%. The treatment was generally well-tolerated, with Grade ≥3 treatment-related adverse events reported in 15% of patients. The pivotal Phase 2/3 trial is set to begin in Q4 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.06%
Tags
-
Rhea-AI Summary

HOOKIPA Pharma (NASDAQ: HOOK) will host an investor call on June 4, 2024, at 4:15 p.m. ET to discuss promising preliminary results from its Phase 2 clinical trial of HB-200 in combination with pembrolizumab.

The data, presented at the American Society of Clinical Oncology 2024 Annual Meeting, focuses on progression-free survival and overall survival for patients with a Combined Positive Score (CPS) ≥20, targeting human papillomavirus 16 positive head and neck cancer.

The company's proprietary arenavirus platform underpins this new class of immunotherapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.59%
Tags
conferences
-
Rhea-AI Summary

HOOKIPA Pharma announced positive results from its Phase 1/2 trial of HB-200 for HPV16+ head and neck cancers, to be presented at ASCO 2024. The study, which involved 42 patients, showed an objective response rate (ORR) of 53% and a disease control rate (DCR) of 82% among patients with PD-L1 CPS of 20 or higher. HB-200 combined with pembrolizumab exhibited a favorable safety profile, with no treatment-related deaths and low treatment discontinuation rates. Additional data, including preliminary progression-free survival and overall survival, will be presented on June 4, 2024. Preliminary findings from an investigator-initiated trial for HB-200 with chemotherapy in non-metastatic HPV16+ cancers showed promising results, with an 81% deep response rate. Preclinical data for HB-700, targeting KRAS mutations, demonstrated effective T-cell responses and tumor cell killing in mice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.08%
Tags
Rhea-AI Summary

HOOKIPA Pharma Inc. reported its first quarter 2024 financial results and business highlights, focusing on its pivotal trial design for HB-200 in combination with pembrolizumab for HPV16+ recurrent or metastatic OPSCC. The company received FDA clearance for its IND application for HB-700 for KRAS mutated cancers. Financially, HOOKIPA saw total revenues of $36.6 million, driven by milestone payments, resulting in a profitable quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
HOOKIPA Pharma announced the final pivotal Phase 2/3 trial design for HB-200 in combination with pembrolizumab. The trial is for the first-line treatment of patients with HPV16+ recurrent or metastatic oropharyngeal squamous cell carcinoma. The Company has aligned with the FDA and anticipates enrolling the first patient in Q4 2024. The data will be presented at ASCO 2024 Annual Meeting, with two additional abstracts accepted. HOOKIPA's CEO expressed confidence in the trial design and potential for accelerated approval based on favorable results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.18%
Tags
-
Rhea-AI Summary
HOOKIPA Pharma announced FDA clearance of its Investigational New Drug Application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of KRAS-mutated cancers. The program targets five prevalent KRAS mutations in lung, colorectal, pancreatic, and other cancers, potentially benefiting more patients than single mutation inhibitors. The IND submission resulted in a $10 million milestone payment from Roche, giving HOOKIPA full control of the intellectual property portfolio and collaboration rights for the HB-700 program. Preclinical data will be presented at the ASCO 2024 Annual Meeting, showcasing the company's commitment to advancing oncology treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
Rhea-AI Summary
HOOKIPA Pharma Inc. grants 250,000 non-statutory options to its Chief Development Officer, Mark Winderlich, under the 2023 Inducement Plan. The options have an exercise price of $0.76 per share, a ten-year term, and vest over four years. This award was granted as an inducement material to Winderlich's acceptance of employment with HOOKIPA in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.8%
Tags
none
-
Rhea-AI Summary
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumab, receiving PRIME designation from EMA. Investor call scheduled to discuss regulatory interactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
conferences
-
Rhea-AI Summary
HOOKIPA Pharma Inc. reports promising Phase 2 data for HB-200 in combination with pembrolizumab for head and neck cancers. They are finalizing IND activities for HB-700 and progressing on infectious disease programs. Financially, they have a strong cash position of $117.5 million at year end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
Rhea-AI Summary
HOOKIPA Pharma Inc. (HOOK) CFO to present at Leerink Partners Global Biopharma Conference 2024. The company focuses on immunotherapeutics using its proprietary arenavirus platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
conferences
Hookipa Pharma

Nasdaq:HOOK

HOOK Rankings

HOOK Stock Data

9.33M
9.46M
2%
58.65%
0.55%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK